Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

From The Editors

TOP - October 2013 VOL 6, NO 4 published on October 30, 2013 in From the Editors
Patrick J. Medina, PharmD, BCOP
Professor of Clinical and Administrative Sciences
University of Oklahoma College of Pharmacy
Tulsa, OK
Steven Stricker, PharmD, MS, BCOP
Assistant Professor of Pharmacy Practice
McWhorter School of Pharmacy
Samford University
Birmingham, AL

In this month’s issue of The Oncology Pharmacist (TOP), we present the second in a series of articles about oncology pharmacy safety and issues related to hazardous materials in the workplace. Christine Roussel, PharmD, BCOP, and Thomas H. Connor, PhD, discuss the sources of workplace contamination and how healthcare workers may be exposed to hazardous drugs during the course of their duties. Roussel and Connor point out that “Although other routes (inhalation, oral, needlesticks) may be factors in uptake of these drugs, the dermal route appears to be the most common.” They emphasize that “while appropriate facility design and proper equipment are critical, so is a strong employee training program with continuing education” to promote compliance and safety.

October is Breast Cancer Awareness Month. The September 30, 2013, presidential proclamation acknowledging this points out that “This disease touches every corner of the United States—in 2013 alone, more than 230,000 women and over 2,000 men will be diagnosed with breast cancer, and tens of thousands will die from it.” In this issue of TOP, we bring you some of the latest research news as well as present some basic statistics about the disease in Noteworthy Numbers.

Be sure to read the article about the continuing problem of drug shortages. Presentations at the 2013 American Society of Clinical Oncology Annual Meeting confirm that this is a persistent problem that affects how healthcare professionals practice medicine and how patients with cancer receive care. One especially worrisome aspect is how the drug shortages have interfered with patient participation in clinical trials.

Please visit our website, www.TheOncologyPharmacist.com, and tell us what topics you want to see covered in TOP. We appreciate your feedback—positive and negative—about what you see in print and on the website.

Related Items
From the Editors
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - May 2019, Vol 12, No 2 published on May 12, 2019 in From the Editors
From the Editors
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in From the Editors
From the Editor - TOP November 2018
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in From the Editors
From the Editor - TON September 2018
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in From the Editors
From the Editor - TOP August 2018
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in From the Editors
From the Editor - TON July 2018
Beth Faiman, PhD, APRN-BC, AOCN
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in From the Editors
From The Editor - TON March 2018
Beth Faiman, PhD, APRN-BC, AOCN
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in From the Editors
From the Editor
Beth Faiman, PhD, APRN-BC, AOCN
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in From the Editors
From The Editors - TOP November 2017
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in From the Editors
From the Editors
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in From the Editors
Last modified: May 21, 2015